Close
Find out more about EEC news and events and related meetings from other organisations.
EEC Network - Next Meeting, 2025
The next face-to-face meeting of the EEC Network will take place on Monday 30 June and Tuesday 1 July 2025 together with the Bone Cancer Research Trust Advances in Ewing Sarcoma Research Meeting on Wednesday 2 July.
Location: Woburn House, Central London
This is also available on Zoom for those unable to travel to London.
Outline programme
Monday 30 June 2025
11:30-12:30 | Networking lunch
12:30-18:00 | How to improve survival and quality of life for patients with multi-metastatic ES (to include sessions on Systemic therapy (including HDCT); Maintenance therapy; Local therapy; Quality of life; Imaging biomarkers)
18:00-19:00 | Networking drinks reception (venue to be confirmed)
19:30-22:00 | Networking dinner at Tavistock Hotel
Tuesday 1 July 2025
09:00-12:15 | Update on the EEC, clinical trials and NEWTS group. Keynote speaker - Poul Sorensen, IL1RAP ADCs
13:05-17:00 | Patient advocacy session, EEC working group updates, Early career researcher session, Inter-disciplinary research in ES (presentations from EEC working group members)
Wednesday 2 July 2025
10:00-16:30 | Advances in Ewing Sarcoma Research Meeting. Submit your abstract to present to research@bcrt.org.uk by 31 March 2025.
Places are limited so please register soon.
Publication of analysis of data from EE99 and EWING-2008 trials
The paper "Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials" has been published in the European Journal of Cancer.
This arm of the EE99 and Ewing-2008 trials compared VIDE induction therapy in unfavourable localised ES followed by either high-dose chemotherapy (Busulfan-Melphalan) and autologous hematopoietic stem cell transplantation or conventional chemotherapy (vincristine-dactinomycin-ifosfamide - VAI) and evaluated the risk of acute toxicity in each group within different age groups.
The authors conclude that "The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups." The EE99 and Ewing-2008 trial were both closed by the end of 2015. Since then, the Euro Ewing 2012 trial has demonstrated that VDC-IE induction therapy, rather than VIDE, should be the standard of care for all newly-diagnosed ES patients.
Register for the EEC meeting, central London (and virtual), 24-25 June 2024
The next EEC network meeting will be face-to-face in central London on Monday 24 and Tuesday 25 June 2024.
Day 1 will focus on the planning for the next international ES trial and day 2 will include trial updates, EEC progress and a focus on biomarkers as well as presentations from Early Career Researchers. An outline of the programme and venue information can be found here.
Opportunity to present at the EEC network meeting on 25 June 2024 and receive a travel bursary of up to €500
Are you an early career researcher working in the field of Ewing sarcoma? Would you like to present your research at the EEC meeting in London next month? If so, please complete this form by Sunday 12 May 2024 for a decision by 26 May 2024. In return for the opportunity to give a ten-minute presentation on their research, successful applicants will receive expenses for travel, hotel accommodation and subsistence to a maximum of €500. Funding has been generously provided by the Bone Cancer Research Trust.